Potential therapeutic alternative in psychiatric disorders offered by NAC amino acid

Improved understanding of the roles of inflammation and oxidative stress in psychiatric disorders has generated new leads in the search for novel therapies. One such investigative compound currently in clinical trials is an amino acid, N-Acetyl Cysteine (NAC), which appears to reduce the core symptoms of bipolar disorder, schizophrenia, depression, autism and cravings in addictions including cocaine, cannabis abuse and cigarette smoking. At the start of the decade of the brain, in the early 1990s, there was great hope that a flurry of new treatment discoveries would eventuate...